Uxin Form 4 Filed by Dai Kun for Oct. 28
A Form 4 for Uxin Ltd. was filed by Dai Kun for Oct. 28.
Related stories
Analysts Raise Price Targets for Axogen After Q3 Results
Truist and Barclays lifted Axogen price targets to $60, from $53 and $50, respectively; Wells Fargo raised its target to $56 from $48. Truist and Barclays maintained Buy ratings.
M impact | EQUITY | Oct 29, 2026, 06:03 PM UTC
Darling Ingredients Reports Q3 2026 Adjusted EBITDA of $514 Million
Darling Ingredients reported Q3 2026 net income of $267 million, reduced net debt by $420 million during the period and reaffirmed full-year 2026 EBITDA guidance of $2.2 billion to
M impact | EQUITY | Oct 29, 2026, 06:03 PM UTC
Bunge Reports Third-Quarter 2026 Revenue of $23.8 Billion, EPS
Bunge reported GAAP diluted EPS of $1.64, versus $0.86 a year earlier, and adjusted EPS of $2.56, versus $2.27. It reiterated full-year adjusted EPS guidance of $9.25 to $9.75.
M impact | EQUITY | Oct 29, 2026, 06:03 PM UTC
Alnylam Q3 Revenue Reaches $1.46 Billion; Reaffirms 2026 Guidance
Q3 revenue exceeded FactSet consensus of $1.43 billion, with adjusted earnings of $16.26 per share. Product sales rose 59% year over year to $1.15 billion; the company cited slower
M impact | EQUITY | Oct 29, 2026, 06:03 PM UTC
Instacart Reports Q3 2026 Revenue of $1.095 Billion, Up 17%
Instacart reported GTV of $10.528 billion, up 15% year over year, and GAAP net income of $147 million, up 2%. Advertising and other revenue rose 23% to $331 million. Following the
M impact | EQUITY | Oct 29, 2026, 06:03 PM UTC
Establishment Labs reports quarterly results for period ended September 30
The results summary was machine generated from LSEG data. The supplied text provides no financial figures.
M impact | EQUITY | Oct 29, 2026, 06:02 PM UTC